Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • Careers
  • Investors
  • News
    • Press Release Archive
    • Press Statements
    • Podcasts
      • The Antigen Podcast
      • Get Science Podcast
      • Diverse Perspectives Podcast
      • menopause: unmuted
      • Hemcast
    • Contact Media Relations
    • Press Kits & Downloads
      • Company Press Kit
      • Pfizer Oncology Press Kit
      • PSA Narrative
      • RA NarRAtive
      • Rare Disease Gene Therapy Press Kit
      • ATTR-Amyloidosis Press Kit
      • UC Narrative
      • Eczema Inside Out Press Kit
  • Partners
    • Discovery to Pre-candidate
      • Focus Areas
        • Therapeutic Areas
          • Internal Medicine
          • Inflammation and Immunology
          • Oncology
          • Rare Disease
          • Vaccines
        • Therapeutic Modalities and Technology Platforms
          • Drug Safety
          • Gene Therapy
          • Target Sciences
          • Precision Medicine
          • Medicinal Sciences
            • Biologics Product & Process Development
            • Biotherapeutics Discovery
            • Medicine Design
            • Small Molecule Product & Process Development
        • Emerging Science
          • DNA Damage Response
          • Microsatellite Repeat Expansions
          • Senescence
      • Partnering Models
    • Candidate Through Commercialization
      • Focus Areas
        • Internal Medicine
        • Inflammation and Immunology
        • Oncology
        • Rare Disease
        • Vaccines
        • Hospital
    • Pfizer CentreOne
    • Pfizer Ventures
      • Our portfolio

Healthcare Professionals

  • Healthcare Professionals

Connect with Us

  • Connect with Us
    • Email
    • FAQ
    • Privacy Policy (NEW)
    • YouTube
    • Twitter
    • Facebook
    • LinkedIn
    • Instagram
  • Your Health

    • Healthy Living
      • Brain & Nervous System
      • Cardiovascular Health
      • Cold & Flu
      • Digestive Health
      • Healthier Aging
      • Living Tobacco Free
      • Men’s Health
      • Mental Health
      • Nutrition & Fitness
      • Pediatric Health
      • Respiratory Health
      • Skin Health
      • Vaccines & Prevention
      • Women’s Health

    • Disease & Condition
      • Cancer
      • Cardiovascular Diseases & Conditions
      • Diabetes & Metabolic Disorders
      • Immune System Diseases & Conditions
      • Infections & Infectious Diseases
      • Neurological Diseases & Conditions
      • Menopause
      • Rare Disease
      • Vaccine-Related Conditions
      • Skin Diseases & Conditions
      • Atopic Dermatitis
      • Cardiovascular Disease
      • Severe Hypertriglyceridemia

    • Coronavirus disease (COVID-19) Resources

    • Managing your health
      • Caregiving
      • Evaluating Health Information
      • Tracking Your Health
      • Your Medicines
      • Health Literacy

    • Wellness
    Hot Topics

    Maintaining Emotional Well-Being During COVID-19

    Emotional Well-Being Tips for People Living with Chronic Inflammatory Conditions During COVID-19
  • Our Science

    • Driven to Discover the cure

    • Focus Areas
      • Internal Medicine
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Anti Infectives

    • Product Pipeline

    • Clinical Trials
      • Guide to Clinical Trials
      • Find a Trial
      • Expanded Access & Compassionate Use
      • Clinical Trials in Children
      • Partnering with Pfizer
      • Trial Data & Results
      • Research Integrity & Transparency
      • Diversity in Clinical Trials

    • R&D Platforms
      • Biosimilars
      • Gene Therapy
      • Medicinal Sciences
      • Precision Medicine
      • Maternal Immunization

    • Collaboration
      • Partner with Pfizer

    • Research sites

    • Coronavirus disease (COVID-19) Resources
      • All COVID-19 Updates
      • Vaccine Efforts
      • Antiviral Efforts
      • Partnerships & Anti-Infective Efforts
      • Supporting the Fight Against COVID-19
    HOT TOPICS

    MRNA VS. CONVENTIONAL VACCINES

    What Makes an RNA Vaccine Different From a Conventional Vaccine?
  • Our People

    • Meet The Experts
      • Scientists
      • Internal Medicine – Metabolic Disease
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Medical Professionals

    • The Journey

    • Leadership
      • Executives
      • Board Members
      • Company Fact Sheet

    • Diverse Perspectives
      • Diversity & Inclusion
      • Supplier Diversity
    HOT TOPICS

    Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron

    dr_richardson_300x170.jpg

    Working Together to Empower Women

    VizagWomen_300x170.jpg

    • Hot Topics
  • Our Purpose

    • Commitment to Global Health
      • Expanding Access
      • Strengthening Health Systems
      • Providing Disaster & Humanitarian Relief
      • Unleashing the Power of Our Colleagues
      • Highlighting Individual Voices

    • Protecting People and the Environment
      • Pfizer's Green Journey
      • Product Stewardship
      • EHS Governance
      • EHS Supply Chain
      • Key Performance Indicators
      • Health & Safety
      • Human Rights

    • Positions on Health Policies
      • Ready for Cures
      • How does Pfizer price medicines?
      • Value of Medicines
      • Policy Positions
      • Creating Cures Through Facility Investments

    • Transparency
      • Working with Health Care Professionals
      • Transparency in Grants
      • Code of Conduct
      • Corporate Compliance
      • Sales and Marketing Compliance

    • Independent Grants
      • Competitive Grants Program
      • Independent Medical Education
      • Investigator Sponsored Research
      • Quality Improvement
      • COVID-19 Vaccine Grants

    • Contributions & Partnerships
      • Healthcare Charitable Contributions
      • Lobbying & Political Contributions
    HOT TOPICS

    Pfizer Women’s Resource Group

    Media Name: IWD_Pull_up_Banner_300x170.jpg

    • Hot Topics
  • Our Products

    • Product listing

    • How drugs are made
      • Branded vs. Generic
      • Biologics & Biosimilars
      • Commitment to Quality

    • Distributors
      • Pfizer Distributors
      • Greenstone Distributors

    • Medicine Safety
      • Reporting Adverse Events
      • Making Good Treatment Choices
      • Partnering With Patients
      • Health Literacy
      • Medicine Safety Tips for Patients
      • Counterfeiting
      • Unused Medicines

    • Safety Data Sheets

    • Medical Information Contacts

    • Pfizer Global Supply
    HOT TOPICS

    Universal vs. Single Payer Healthcare

    Media Name: universal_healthcare300x170.jpg
  • Careers

    • Working Here
      • Mission & Purpose
      • Culture
      • Diversity & Inclusion
      • Career Growth & Colleague Development
      • Compensation & Benefits
      • Ensuring Corporate Responsibility
    • Search Jobs
    • Student & Early Career
      • Postdoctoral Program
      • US Summer Student Worker Program
      • Opportunities for Veterans
    • Pfizer365.com
    • Our Hiring & Recruiting Process
      • Frequently Asked Questions
      • Tips for Interviewing at Pfizer
    • Connect With Us
  • Investors

    • Investors Overview
      • Why Invest / Our Story
      • Prospective Investors
      • Fact Sheet
    • Events & Presentations
    • Financials
      • Quarterly Reports
      • Annual Reports
      • SEC Filings
      • Interactive Data Filings
    • Investor News
    • Stock Information
      • Historical Price Lookup
      • Investment Calculator
      • Historical Stock Chart & Data
      • Dividend & Split History
      • Stock FAQs
    • Governance
      • Board Committees and Charters
      • The Pfizer Board Policies
      • Corporate Governance FAQs
      • Contact Our Directors
    • Shareholder Services
      • Stock FAQs
      • Advisory Information
      • Cost Basis Calculator
  • News

    • Contact Media Relations
    • Podcasts
    • Press Kits & Downloads
    • Press Release Archive
    • Press Statements
  • Partners
  • Footer links

    • Footer Aside Section1
      • CAREER-SEEKERS
      • INVESTORS
      • News & Media
      • Partners
    • Footer Aside Section 2
      • Healthcare Professionals
      • Business To Business
      • Change Region
      • Sitemap
    • Footer Aside Section3
      • Twitter
      • Facebook
      • Linkedin
      • Instagram
      • Youtube
    • Footer Aside Section4
      • Contact Us
      • Terms of Use
      • Privacy Policy

A Day in the Life of a Scientist (In the time of Coronavirus)

A Day in the Life of a Scientist (In the time of Coronavirus)
OUR PEOPLE/ A Day in the Life of a Scientist (In the time of Coronavirus)
April 17, 2020

A Day in the Life of a Scientist (in the Time of Coronavirus)

“I feel extremely privileged to have a career where I can both contribute to public health and conduct research that furthers the field of microbiology,” says Liesa.

Meet Dr. Annaliesa Anderson, Pfizer’s Chief Scientific Officer of Bacterial Vaccines within the Vaccine Research and Development group. Liesa, as she is affectionately called by her family and peers, has spent the last 13 years at Pfizer working to develop new vaccines that prevent infectious diseases caused by bacteria. She earned her Ph.D. in Biological Sciences from the University of Warwick in the U.K. and has spent most of her career studying microbiology.

On a typical day, you would find Liesa working at a Pfizer research site but that was before coronavirus became a global pandemic. Now, she spends most of her days at home in New Jersey with her husband, two teenagers, and dog. Here, she shares what life is like, for a microbiologist, in the time of coronavirus.

First, balance doesn’t always exist.

As a scientist, like many of my peers, I am engrossed in the science of our current situation. So, it’s very easy to forget to find a balance between my work and home life. I can safely say that for those of us in this field of research and development, we are passionate about vaccines and their role in public health. We work on developing vaccines where there is a defined medical need. For the current COVID-19 pandemic, the motivations for developing a vaccine are of course the same. If we can develop a vaccine that can prevent the disease from happening in the first place, we have the best chance at eradicating the disease. We all have loved ones who are currently housebound and many of us know people who are suffering with disease. Our primary goal is to try to stop this from happening again. The concept that this virus has no known cure is very emotive and brings us back to what it must have been like a hundred years before the golden age of antibiotics, which have been so effective at treating bacterial infections. The infectious disease community is tremendously motivated to identify better approaches to treat COVID-19, to improve the outcome for patients. I think multi-pronged approaches for prevention and treatment have a good chance of success and it is incredibly motivating to have the opportunity to be involved in these efforts.

Settling into my “research lab” at home.

I have colleagues going to lab and other facilities every day to do critical work associated with developing the COVID-19 vaccine and treatments, attempting to ensure that our other vaccine development programs are not majorly impacted and that supplies of vaccines and essential medicines are uninterrupted, and keeping the facilities going to support these activities. I have recently been going to the office once a week to help with on-site activities and I spend the rest of my time working from home. We are all adapting to working from home. I try to use my video feature on my conference calls as much as possible, as it can be both isolating and disengaging not to see my colleagues. It always brings a smile to everyone’s faces when colleagues’ children and pets make surprise appearances.

Collaboration and connection leads to success.

I’m very lucky to be working at Pfizer, where we have many skilled and talented scientists and clinicians who are working hard to make a vaccine and treatments for COVID-19 a reality. Likewise, we are working closely with scientists at academic institutes who have devoted their careers to learning about coronaviruses. It’s a great example of how academia and companies such as Pfizer can work together. Although COVID-19 is an infectious disease, it isn’t caused by bacteria, which is what I specialize in. It’s caused by a virus which makes this time even more interesting for me as I have spent the majority of my career conducting research and development into bacterial vaccines. So, even though many of the principals around research and development are similar, there are differences. I’m extremely lucky to be working with brilliant chemists such as Dr Charlotte Allerton, who leads Pfizer’s Medicinal Sciences organization and has been instrumental in helping to advance the investigation of a promising compound that we are working on to potentially treat COVID-19 patients. This compound is designed to potentially stop the virus from growing by inhibiting an enzyme called the 3CL protease. Because of this, it belongs to a class of compounds known as protease inhibitors.

With infections, history often repeats itself.

We have to repeat experiments many times to establish accurate data. In the case of the protease inhibitor program that was first initiated by Pfizer in 2003, when the world saw another coronavirus cause the SARS epidemic, our scientists were working on ways to treat SARS patients. At the time, a compound was discovered that showed great promise in the laboratory, however it did not continue to clinical development because the SARS epidemic had resolved. Now, 17 years later, we are in the midst of a pandemic caused by a related coronavirus. We still have many scientists who were involved with the initial program and they were able to use molecular modeling to show that the protease for both the SARS and the COVID 19 viruses are very similar. This observation gave us confidence to reactivate the program. We now have data that show that indeed the compound identified as an inhibitor for the coronavirus that causes SARS can inhibit SARS-CoV-2, the COVID-19 associated virus, via its 3CL protease. This is very exciting, but only the beginning. We now need to determine if there is a formulation of the compound that can be used for patients and conduct toxicology and other pre-clinical studies before it can enter clinical testing. We are working closely with regulatory agencies to look for ways to accelerate the potential development of this compound.

And curiosity is an inherent part of the job.

At a time when most people have questions about coronavirus and the current environment that we find ourselves in, I, too, have questions. The first is, obviously, will we succeed in developing vaccines and drugs that can be used to protect the population against COVID-19? With every new data point there are new questions. During my career I’ve seen that there isn’t a right or wrong path, and that ultimately when you make choices one often gets to the same place in the end, but some paths take longer. Rather like a game of Chutes and Ladders. In the current situation, we can’t afford to fall down any chutes, we need to work together to make sure that we are finding all the ladders so we can reach the goals in the most expedited manner.

And, yes, it does keep me up at night. It’s certainly a daunting task to develop vaccines and medicines during a pandemic. The pressure is on and even while the rest of the world is on lock down, we still need scientists to go to the labs every day to do this work. Whether they are our Pfizer scientists or academic collaborators, they are all doing truly amazing work.

When my day job ends, my other life begins.

After my workday ends, I try to spend as much time with my family as possible. I am enjoying having our family home. Our social life is now a Zoom social life, but we’ve had the opportunity to go back to traditions that we had before the kids were out every weekend night. There are lots of family-cooked meals, baking traditional English food (yes there is such a thing) and waving at neighbors from a distance while we walk the dog. My family is my biggest inspiration and they support and motivate me to work on developing preventions and treatments for infectious diseases.

 

MORE ON COVID-19
How to stay safe and prevent the spread.

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at www.cvdvaccine.com.

Related Hot Topics
Albert Bourla Reflects on the One Year Anniversary of the COVID-19 Pandemic
Albert Bourla Reflects on the One Year Anniversary of the COVID-19 Pandemic
Albert Bourla On Ensuring Equitable Access to COVID-19 Vaccines
Albert Bourla On Ensuring Equitable Access to COVID-19 Vaccines
The Facts About Pfizer and BioNTech’s COVID-19 Vaccine
The Facts About Pfizer and BioNTech’s COVID-19 Vaccine
KZOO-Vials-in-Tray-2-(1)_380X220.jpg
Distributing Our COVID-19 Vaccine to the World
Scientists_Image_380X220.jpg
Albert Bourla Discusses Our FDA Submission
Covid Vaccine Study - What's Next
Our COVID-19 Vaccine Study – What’s Next?
KZOO_Filling_Line_10_380X300.jpg
COVID-19 Vaccine U.S. Distribution Fact Sheet
Chronic Stress and How to Manage It
Chronic Stress and How to Manage It
Tags
COVID-19
COVID-19 Vaccine Efforts
Show
Hide

Footer menu

  • Your Health
    • Healthy Living
    • Disease Conditions
    • Manage Your Health
  • Our Science
    • Therapeutic Areas
    • Product Pipeline
    • Clinical Trials
    • R&D Platforms
    • Collaboration
    • Research SItes
  • Our People
    • Meet the Experts
    • The Journey
    • Leadership
    • Diverse Perspectives
  • Our Purpose
    • Commitment To Global Health
    • Positions on Health Policies
    • Transparency
    • Contributions & Partnerships
  • Our Products
    • Product Listing
    • How Drugs are Made
    • Distributors
    • Global Product Information Contacts

Footer aside

  • Footer Aside Section1
    • CAREER-SEEKERS
    • INVESTORS
    • News & Media
    • Partners
  • Footer Aside Section 2
    • Healthcare Professionals
    • Business To Business
    • Change Region
    • Sitemap
  • Footer Aside Section3
    • Twitter
    • Facebook
    • Linkedin
    • Instagram
    • Youtube
  • Footer Aside Section4
    • Contact Us
    • Terms of Use
    • Privacy Policy
Pfizer Logo Footer

Copyright © 2002-2021 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.